The Influence of Metastatic Lymph Node Ratio ... - KoreaMed Synapse

0 downloads 0 Views 330KB Size Report
Youjin Kim, Se Hoon Park, Kyoung-Mee Kim', Min Gew ChoiÅ¿, Jun Ho Lee, Tae Sung Sohn, Jae Moon Bae,. Sung Kim, Su Jin Lee, Seung Tae Kim, Jeeyun Lee, ...
pISSN : 2093-582X, eISSN : 2093-5641 J Gastric Cancer 2016;16(2):105-110  http://dx.doi.org/10.5230/jgc.2016.16.2.105

Original Article

The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial Youjin Kim, Se Hoon Park, Kyoung-Mee Kim1, Min Gew Choi2, Jun Ho Lee2, Tae Sung Sohn2, Jae Moon Bae2, Sung Kim2, Su Jin Lee, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, and Won Ki Kang Division of Hematology-Oncology, Department of Medicine, 1Department of Pathology, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2

Purpose: In the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial, we investigated whether chemoradiotherapy after D2 gastrectomy reduces the rate of recurrence. Recently, the ratio of metastatic lymph nodes to examined lymph nodes (N ratio) has been proposed as an independent prognostic factor in gastric cancer (GC). The aim of this study was to investigate the relationship between the metastatic N ratio and prognosis of GC after curative D2 surgery. Materials and Methods: We retrospectively reviewed the data of 458 ARTIST patients who underwent D2 gastrectomy followed by adjuvant chemotherapy (XP, n=228) or chemoradiotherapy (XPRT, n=230). The disease-free survival (DFS) rates of patients were used to evaluate the influence of N ratio on the treatment outcome. To achieve this, 4 different N ratio categories (0%, 1%~9%, 10%~25%, and >25%) were compared on the basis of their influence on the treatment outcome. Results: On multivariate analysis, the N ratio remained an independent prognostic factor for DFS. The hazard ratios (HRs) for the N ratio categories of 0%, 1%~9%, 10%~25%, and >25% were 1, 1.061, 1.202, and 3.571, respectively. In patients having N ratio >25%, the 5-year DFS rates were 55% and 28% for the XPRT and XP arms, respectively (HR, 0.527; 95% confidence interval, 0.307~0.904; P=0.020). Conclusions: In patients with curatively resected GC, the N ratio was independently associated with DFS. Although this finding warrants further investigation in future prospective studies, the benefit of chemoradiotherapy for D2 resected GC appears to be more beneficial in cancers having N ratios >25%. Key Words: Stomach neoplasms; Lymph node; Prognosis

DBODFS ($

BTJHOJGJDBOUQSPQPSUJPOPGQBUJFOUTVOEFSHPJOHDV

Introduction

SBUJWFTVSHFSZFYQFSJFODFEJTFBTFSFDVSSFODFUIBUSFTVMUTJOQPPS "MUIPVHITVSHJDBMSFTFDUJPOXJUISFHJPOBMMZNQIOPEF -/ 

QSPHOPTJT3FHJPOBM-/EJTTFDUJPOQFSGPSNFEBUUIFUJNFPGDV

EJTTFDUJPOJTUIFPOMZDVSBUJWFUSFBUNFOUGPSQBUJFOUTXJUIHBTUSJD

SBUJWFHBTUSFDUPNZQSPWJEFTJNQPSUBOUQBUIPMPHJDBMJOGPSNBUJPO GPSQSFEJDUJOHQBUJFOUQSPHOPTJT"MUIPVHIDPOWJODJOHFWJEFODF

Correspondence to: Se Hoon Park Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea Tel: +82-2-3410-1767, Fax: +82-2-3410-1754 E-mail: [email protected] Received April 28, 2016 Revised May 16, 2016 Accepted May 20, 2016

TVQQPSUJOH%-/EJTTFDUJPOJTBCTFOUJOUIF8FTUFSOMJUFSBUVSF  UIJTQSPDFEVSFJTBMSFBEZDPOTJEFSFEBTUBOEBSEUSFBUNFOUPQUJPO JO"TJBODPVOUSJFTTVDIBT,PSFBBOE+BQBO.FUJDVMPVT-/EJT TFDUJPONJHIUOPUPOMZJEFOUJGZUIFQBUJFOUTXIPSFRVJSFBEKVWBOU DIFNPUIFSBQZPXJOHUPUIFIJHISFDVSSFODFSJTLBGUFSTVSHFSZ   CVUNJHIUBMTPCFDVSBUJWFJOTPNFPGUIFQBUJFOUTIBWJOHQPTJ UJWF-/T*OUIF"EKVWBOU$IFNPSBEJPUIFSBQZJO4UPNBDI5V

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyrights © 2016 by The Korean Gastric Cancer Association

www.jgc-online.org

106 Kim Y, et al.

NPST "35*45 SBOEPNJ[FEQIBTF***USJBM  XFDPNQBSFEUIF

4FPVM ,PSFB JOBDDPSEBODFXJUIUIFFUIJDBMQSJODJQMFTPGUIF

PVUDPNFTPGBEKVWBOUDBQFDJUBCJOFDJTQMBUJO 91 DIFNPUIFSBQZ

%FDMBSBUJPOPG)FMTJOLJBOEMPDBMHVJEFMJOFT8SJUUFOJOGPSNFE

BOEBEKVWBOUDIFNPSBEJPUIFSBQZ 9135 BGUFSDVSBUJWF%HBT

DPOTFOUXBTPCUBJOFEGSPNBMMQBSUJDJQBUJOHQBUJFOUTCFGPSFUIFZ

USFDUPNZGPS($"MUIPVHIUIJTUSJBMGBJMFEUPEFNPOTUSBUFBO

XFSFSBOEPNMZBTTJHOFEUPHSPVQT

PWFSBMMEJGGFSFODFJOEJTFBTFGSFFTVSWJWBM %'4 CFUXFFOUIF

4VSHJDBMTQFDJNFOTXFSFSPVUJOFMZBTTFTTFECZPVSEFEJDBUFE

UXPUSFBUNFOUHSPVQT TVCHSPVQBOBMZTJTJOEJDBUFEUIBUBEKVWBOU

HBTUSPJOUFTUJOBMQBUIPMPHJTUT5IFUPUBMOVNCFSPG-/TBOEUIF

9135NJHIUCFNPSFCFOFGJDJBMJOQBUJFOUTIBWJOH-/QPTJUJWF

OVNCFSPGQPTJUJWF-/TXFSFSFQPSUFE"UMFBTU-/TXFSFSF

EJTFBTFT ZFBS%'4 JOUIF9135BSNWTJOUIF91

NPWFEJOPGUIFQBUJFOUTFOSPMMFEJOUIF"35*45USJBM5IF

BSN1 

/SBUJPTXFSFEJWJEFEJOUPDBUFHPSJFTBDDPSEJOHUPUIFEFTDSJQ

$POTJEFSJOHUIFIJHISFDVSSFODFSBUFBOEQPPSQSPHOPTJTBT TPDJBUFEXJUI($QBUJFOUT JUJTJNQPSUBOUUPJEFOUJGZQBUJFOUTBU

UJPOTCZ/JUUJFUBMBOE.BSDIFUFUBMBTGPMMPXTDBUFHPSZ  DBUFHPSZ _DBUFHPSZ _BOEDBUFHPSZ ⾚

IJHISJTLGPSSFDVSSFODF*OBEEJUJPOUP-/QPTJUJWJUZ UIFUPUBM

5IFDVUPGGEBUFGPSUIFBOBMZTJTXBT4FQUFNCFS XJUI

OVNCFSPG-/TSFNPWFE JTBOJOEJSFDUNFBTVSFPGUIFFYUFOU

BNFEJBOGPMMPXVQEVSBUJPOPGZFBST5IF$PYQSPQPSUJPOBM

PG-/EJTTFDUJPO BOEJUTFSWFTBTBOJNQPSUBOUGBDUPSJO($

IB[BSETNPEFMXJUICBDLXBSETFMFDUJPOXBTVTFEJOUIFBOBMZTFT



TVSHFSZ *OUIFMJHIUPGTVDIGJOEJOHT TPNFQSFWJPVTTUVEJFT

PGUIFDPSSFMBUJPOTCFUXFFOCBTFMJOFDIBSBDUFSJTUJDTJODMVEJOHUIF

IBESFDPNNFOEFEUIFVTFPGUIFSBUJPPGNFUBTUBUJD-/TUPFY

/SBUJP BOEUIF%'4BOE04BTFOEQPJOUT*OEJWJEVBMGBDUPST

BNJOFE-/T /SBUJP BTBQSPHOPTUJDGBDUPSJSSFTQFDUJWFPGUIF

UIBUTIPXFEQSPHOPTUJDTJHOJGJDBODFJOUIFVOJWBSJBUFBOBMZTFT

UZQFPG-/EJTTFDUJPOQFSGPSNFE )PXFWFS UIFTFTUVEJFTXFSF

XFSFUFTUFEGPSUIFJSDPNCJOFEQSPHOPTUJDTJHOJGJDBODFJOBNVM

MJNJUFECZUIFJSSFUSPTQFDUJWFOBUVSF BOEUIFQSPHOPTUJDWBMVFPG

UJWBSJBUF$PYSFHSFTTJPONPEFM5IFWBSJBCMFTUIBUXFSFJODMVEFE

/SBUJPIBTOPUZFUCFFOQSPTQFDUJWFMZBEESFTTFE*OUIFQSFTFOU

JOUIFNVMUJWBSJBUFNPEFMGPSUIFJEFOUJGJDBUJPOPGUIFQSPHOPTUJD

TUVEZ XFVTFEEBUBPCUBJOFEGSPNUIFQSPTQFDUJWF"35*45USJBM

GBDUPSTPG%'4BOE04XFSFUIFBHF ⾘ZFBSTWTⴎZFBST 

UPFYBNJOFUIFSFMBUJPOTIJQCFUXFFOUIF/SBUJP EFGJOFEBTUIF

TFY NFOWTXPNFO &BTUFSO$PPQFSBUJWF0ODPMPHZ(SPVQ

OVNCFSPGQPTJUJWF-/TUIFUPUBMOVNCFSPG-/TSFNPWFE BOE

&$0( QFSGPSNBODFTUBUVT WT -BVSFODMBTTJGJDBUJPO JO

%'4PSPWFSBMMTVSWJWBM 04 JO($QBUJFOUTXIPVOEFSXFOUDV

UFTUJOBMWTEJGGVTFWTNJYFE UVNPSMPDBUJPO QSPYJNBMCPEZWT

SBUJWFHBTUSFDUPNZXJUI%-/EJTTFDUJPO

BOUSVNWTNVMUJQMFEJGGVTF UZQFPGTVSHFSZ TVCUPUBMWTUPUBM HBTUSFDUPNZ -/TUBUVT OFHBUJWFWTQPTJUJWF TUBHF ***WT***

Materials and Methods

*7 BOEUIF/SBUJP5IFQPUFOUJBMQSFTFODFPGBOJOUFSBDUJPO CFUXFFOBHFBOEPUIFSDMJOJDBMQBSBNFUFSTXBTUFTUFECZEFGJO

5IFDPNQMFUFEFUBJMTPGUIF"35*45USJBMXFSFQSFWJPVTMZ

JOHUIFQSPEVDUUFSNTGPSUIFSFTQFDUJWFGBDUPSTJOBSFHSFTTJPO

QVCMJTIFEFMTFXIFSF*OCSJFG QBUJFOUTXJUIQBUIPMPHJDTUBHF

NPEFM5IFWBSJBCMFTUIBUXFSFJEFOUJGJFEUPCFJOTJHOJGJDBOUXFSF

*C–*7 . ($TBDDPSEJOHUPUIF"NFSJDBO+PJOU$PNNJUUFFPO

ESPQQFEPOFBUBUJNF CFHJOOJOHXJUIUIFMFBTUTJHOJGJDBOUWBSJ

$BODFSTUBHJOHTZTUFNXFSFSBOEPNMZBTTJHOFEUPSFDFJWF

BCMF4VSWJWBMDVSWFTXFSFHFOFSBUFEVTJOHUIF,BQMBO.FJFS

BEKVWBOU91 O PS9135 O 5IFUSFBUNFOUSFHJNFO

NFUIPE"MM1WBMVFTXFSFUXPTJEFE BOEUIPTF⾘XFSF

BENJOJTUFSFEJOUIF91BSNJODMVEFEDZDMFTPG NHN

DPOTJEFSFETUBUJTUJDBMMZTJHOJGJDBOU"MMTUBUJTUJDBMBOBMZTFTXFSF

DBQFDJUBCJOFBENJOJTUFSFEUXJDFEBJMZPOEBZTUPBOE

QFSGPSNFEVTJOHUIF1"484UBUJTUJDTTPGUXBSFWFSTJPO *#.



NHN DJTQMBUJOPOEBZ6QUPDZDMFTPG91XBTBENJOJT

$P "SNPOL /: 64" 

UFSFEFWFSZXFFLT5IFUSFBUNFOUSFHJNFOBENJOJTUFSFEJOUIF 9135BSNJODMVEFEUIFDPODPNJUBOUBENJOJTUSBUJPOPGBUPUBM

Results

SBEJPUIFSBQZEPTFPG(ZBOENHNDBQFDJUBCJOFUXJDF EBJMZBGUFSUIFDPNQMFUJPOPGUXPDZDMFTPG91 GPMMPXFECZUIF

0GUIFQBUJFOUTFOSPMMFEJOUIF"35*45USJBM DBTFT

BENJOJTUSBUJPOPGUXPBEEJUJPOBMDZDMFTPG913BEJPUIFSBQZXBT

 XFSF-/QPTJUJWFBOEDBTFT  XFSF-/OFHBUJWF

BENJOJTUFSFEJOEBJMZGSBDUJPOTPG(ZEBJMZ EBZTQFSXFFL 

5BCMF "MMQBUJFOUTVOEFSXFOUDVSBUJWFHBTUSFDUPNZXJUI

PWFSBQFSJPEPGXFFLT5IF"35*45USJBMXBTBQQSPWFECZ

%-/EJTTFDUJPOBOETVCTFRVFOUMZ UIFZXFSFSBOEPNMZBT

UIFJOTUJUVUJPOBMSFWJFXCPBSEPGUIF4BNTVOH.FEJDBM$FOUFS

TJHOFEUPSFDFJWFFJUIFSBEKVWBOU91 O PS9135 O 

107 Prognostic Value of LN Ratio after D2 Gastrectomy

5IFNFEJBOOVNCFSTPG-/TSFNPWFEBOE-/TJOWPMWFEXFSF

Table 1. Baseline patient characteristics

DBTFT SBOHF _DBTFT BOEDBTFT SBOHF _DBTFT

 Characteristic Age (yr)

Data

SFTQFDUJWFMZ5IFOVNCFSPG-/TSFNPWFEEJEOPUEJGGFSTJHOJGJ

56 (22~77)

DBOUMZCFUXFFOQBUJFOUTXJUITUBHF*C**BOE****7 . EJTFBTF

Sex

5IFGJOBMBOBMZTFTTIPXFEUIBU%'4 IB[BSESBUJP 

Men

296 (64.6)

DPOGJEFODFJOUFSWBM _1 BOE04 )3 

Women

162 (35.4)

$* _1 GPSUIF9135BOE91BSNT

Pathological stage*

XFSFTJNJMBS5IFZFBS%'4BOE04SBUFTXFSFBOE 

IB/II

269 (58.7)

SFTQFDUJWFMZ GPS-/OFHBUJWFQBUJFOUT BOEBOE SF

III/IV (M0)

189 (41.3)

TQFDUJWFMZ GPSQBUJFOUTXJUI-/JOWPMWFNFOU

N stage

"DDPSEJOHUPUIFUJFSDMBTTJGJDBUJPOPGUIF/SBUJP UIF

pN0

62 (13.5)

ZFBS%'4SBUFTGPSQBUJFOUTIBWJOH/SBUJPTPG _ 

pN1

253 (55.2)

_ BOE⾚XFSF   BOE SFTQFD

pN2

101 (22.1)

pN3

42 (9.2)

No. of lymph nodes removed

40 (12~142)

No. of lymph nodes involved

3 (0~51)

UJWFMZ5IFDPSSFTQPOEJOHZFBS04SBUFTXFSF    BOE SFTQFDUJWFMZ5IF,BQMBO.FJFSDVSWFTGPS%'4BOE 04BSFTIPXOJO'JH$POTJEFSJOHUIFTJNJMBSJUJFTJOUIF)3T

Lymph node ratio† 0

62/14

1~9

172/38

10~25

133/29

>25

Table 2. Disease-free survival and overall survival according to lymph node ratio Disease-free survival

N ratio (%)

91/20

Adjuvant treatment

HR

95% CI

Overall survival

P-value

HR

95% CI

P-value

XP

228 (50.0)

0

1

XPRT

230 (50.0)

1~9

0.79

0.40~1.55

10~25

0.89

0.44~1.79

0.743 1.25 0.64~2.43

0.518

>25

3.31

1.75~6.24

25%

0.2 0

0

6

12

18

24

30

36

42

48

54

60

Months

Fig. 1. (A) Disease-free survival curves according to N ratio. (B) Overall survival curves according to N ratio. The cut-off values for the N ratios are as follows: solid (black) line, 0%; dashed line, 1~9%; dotted line, 10~25%; and solid (gray) line, ⾚25%. N ratio = the ratio of metastatic lymph nodes to examined lymph nodes.

108 Kim Y, et al.

A

B

1.0

1.0

P=0.312

0.8

Probability

Probability

0.8 0.6 0.4 0.2 0

P=0.35

6

12

18

24

30

36

42

48

54

0.4 0.2

XPRT arm XP arm 0

0.6

0

60

XPRT arm XP arm 0

6

12

18

24

Months

30

36

42

48

54

60

Months

Fig. 2. (A) Disease-free survival curves for patients with N ratios of 0%~25%. (B) Overall survival curves for patients with N ratios of 0%~25%. Solid line, XPRT arm; dotted line, XP arm. XP = capecitabine plus cisplatin; XPRT = concurrent chemoradiotherapy with XP; N ratio = the ratio of metastatic lymph nodes to examined lymph nodes.

A

B

1.0

1.0

P=0.02

0.8

Probability

Probability

0.8 0.6 0.4 0.2 0

P=0.05

XPRT arm XP arm 0

6

12

18

24

30

36

42

48

54

60

Months

0.6 0.4 0.2 0

XPRT arm XP arm 0

6

12

18

24

30

36

42

48

54

60

Months

Fig. 3. (A) Disease-free survival curves for patients with N ratios >25% (B) Overall survival curves for patients with N ratios >25%. Solid line, XPRT arm; dotted line, XP arm. XP = capecitabine plus cisplatin; XPRT = concurrent chemoradiotherapy with XP; N ratio = the ratio of metastatic lymph nodes to examined lymph nodes.

GPS%'4BOE04FOEQPJOUTGPSUIF/SBUJPPGUP 5BCMF



9135BOE91BSNTBOEUIF/SBUJPXFSFPCTFSWFE5IF%'4

XFFNQMPZFEBEJDIPUPNPVTDMBTTJGJDBUJPO JF UJFS _

SBUFTGPSUIF9135BOE91BSNTTIPXFEOPTJHOJGJDBOUEJGGFS

WT⾚ *OUIF$PYSFHSFTTJPOBOBMZTFTPGUIFGBDUPSTBTTPDJ

FODFTJOQBUJFOUTXJUI/SBUJPTPG_ )3 $* 

BUFEXJUI%'4BOE04 TJHOJGJDBOUJOUFSBDUJPOTXFSFJEFOUJGJFE

_1 )PXFWFS JOQBUJFOUTXJUI/SBUJPT⾚

CFUXFFOUVNPSMPDBUJPOBOEUIFUZQFPGTVSHFSZ CFUXFFOTUBHF

'JH

UIF%'4JOUIF9135BSNXBTTJHOJGJDBOUMZMPOHFSUIBO

BOE-/TUBUVT BOECFUXFFO-/TUBUVTBOE/SBUJP5IFGJOBM

UIBUJOUIF91BSN )3 $* _1 "M

NPEFMBEKVTUFEGPSUIFEJGGFSFODFTJODMJOJDBMDIBSBDUFSJTUJDT

UIPVHIMFTTTJHOJGJDBOUMZ UIF04JOUIF9135BSNXBTMPOHFS

TIPXFEUIBUUIFNPTUTJHOJGJDBOUQSFEJDUPSPGSFDVSSFODFXBTUIF

UIBOUIBUJOUIF91BSNGPSQBUJFOUTXJUI/SBUJPT⾚ )3 

/SBUJP⾚ BEKVTUFE)3 $* _1⾘ 

$* _1'JH 

4JNJMBSMZ QBUJFOUTXJUI/SBUJPT⾚XFSFNPSFMJLFMZUPEJF DPNQBSFEUPUIPTFIBWJOH/SBUJPT_ BEKVTUFE)3 

Discussion

$* _1⾘  *OUIF"35*45USJBM TJHOJGJDBOUJOUFSBDUJPOTCFUXFFOUIF

5IFQSFTFOUTUVEZDPOGJSNFEUIBUUIFQSPHOPTUJDSPMFPG/

109 Prognostic Value of LN Ratio after D2 Gastrectomy

SBUJPXBTJOEFQFOEFOUPGUIFQBUIPMPHJDBMTUBHFPGUIFEJTFBTF

MBDLPGBDMFBSEJTUJODUJPOCFUXFFOUIF%'4BOE04DVSWFTGPS

PSPUIFSQSPHOPTUJDGBDUPSTJOBQSPTQFDUJWFBEKVWBOUUSJBM5IF

UIF/SBUJPTPGBOEBGUFSUIFSJTLPGFWFOUTQMBUFBVFE

/TUBHFXBTOPUJODMVEFEJOUIFGJOBM$PYNPEFMEVFUPJUTTJH

/PUTVSQSJTJOHMZ XIFOXFUFTUFEUIFBTTPDJBUJPOCFUXFFOUIF/



OJGJDBOUJOUFSBDUJPOXJUIUIF/SBUJP 5IFSFTVMUTPGUIFBOBMZTJT

SBUJPBOE%'4JOQBUJFOUTXJUI-/QPTJUJWFEJTFBTF TJNJMBS

TUSPOHMZTVHHFTUFEUIBUUIF/SBUJPQSPWJEFTBNPEFMXJUIHSFBUFS

SFTVMUTXFSFPCUBJOFE*O-/OFHBUJWFQBUJFOUT JF /SBUJP



QSPHOPTUJDQPXFSUIBOUIBUPCUBJOFEVTJOHUIF/TUBHF0VSSF

UIFCFOFGJDJBMFGGFDUPGFYUFOEFE-/EJTTFDUJPOIBTPGUFOCFFO

TVMUTBSFDPOTJTUFOUXJUIUIPTFPGQSFWJPVTSFUSPTQFDUJWFTUVEJFT

MJOLFEUPTUBHJOHUIBUJTNPSFBDDVSBUF5IFSFNPWBMPGNPSF

UIBUSFQPSUFEUIF/SBUJPBTBOFGGFDUJWFQSPHOPTUJDUPPMBGUFS%

-/TNJHIUQPTTJCMZCFBTTPDJBUFEXJUIBNPSFBDDVSBUFGJOBM

  

'VSUIFS

QBUIPMPHJD/TUBHJOHJUJTXFMMFTUBCMJTIFEUIBUQBUJFOUTXJUIPVU

NPSF XFGPVOEUIBUQBUJFOUTXJUI/SBUJPT⾚XPVMECFOFGJU

-/NFUBTUBTFTFYIJCJUNVDICFUUFSTVSWJWBMDPNQBSFEUPQBUJFOUT

GSPNUIFBEEJUJPOPGSBEJPUIFSBQZUPBEKVWBOU91DIFNPUIFSBQZ

XJUI-/JOWPMWFNFOU"MUFSOBUJWFMZ FWFOJOQBUJFOUTXJUIQ/

4VSHFPOTXPVMECFNPSFMJLFMZUPSFTFDUBIJHIFSOVNCFSPG

EJTFBTF SFNPWJOHNPSF-/TUIBUBSFOFHBUJWFDPVMESFTVMUJOUIF

-/TVQPOUIFJEFOUJGJDBUJPOPGQPTJUJWFPSTVTQJDJPVT-/TEVSJOH

DMFBSBODFPGNJDSPNFUBTUBUJDDBODFSGPDJUIBUBSFOPUEFUFDUFEPO

HBTUSFDUPNZ5IFMJLFMJIPPEPGEFUFDUJOH-/QPTJUJWFEJTFBTF

QBUIPMPHJDBTTFTTNFOU*UJTMJLFMZUIBUBQPSUJPOPGUIFJNQSPWFE

JODSFBTFEXJUIBOJODSFBTFJOUIFOVNCFSPGSFTFDUFE-/TIPX

TVSWJWBMUIBUXBTPCTFSWFEXJUIFYUFOEFE-/EJTTFDUJPOJOQB

FWFS UIJTBMTPJOEJDBUFEBIJHIFSMJLFMJIPPEGPSBMPXFS/SBUJP

UJFOUTXJUIPVU-/JOWPMWFNFOUDPVMECFBUUSJCVUFEUPUIFDMFBS

"MUIPVHIUIFSFJTDVSSFOUMZOPDPODMVTJWFFWJEFODFTVQQPSUJOH

BODFPGUIFTFNJDSPNFUBTUBTFT

HBTUSFDUPNZJOBEEJUJPOUPMJNJUFE-/EJTTFDUJPO

UIFVTFPGBEKVWBOU9135BGUFS%TVSHFSZ NPSFFYUFOTJWF-/

*O($QBUJFOUTXIPVOEFSXFOU%-/EJTTFDUJPO BEKV

EJTTFDUJPONJHIUJNQSPWFUIFRVBMJUZPGMPDBMDPOUSPMBOENJHIU

WBOUDIFNPUIFSBQZJOWPMWJOHFJUIFS4NPOPUIFSBQZPS

CFUUFSJEFOUJGZUIFQBUJFOUTXIPNJHIUCFTUCFOFGJUGSPNBEEJ

DBQFDJUBCJOFPYBMJQMBUJODPNCJOBUJPOUIFSBQZJTDPOTJEFSFEUIF



UJPOBM9135*OUIF"35*45USJBM UIFNFEJBOOVNCFSPG-/T

TUBOEBSEUSFBUNFOU *OUIF"35*45USJBM  9135EJEOPUTJH

SFNPWFEXBTIPXFWFS UIFSBOHFXBTBTXJEFBTUP

OJGJDBOUMZSFEVDFSFDVSSFODFDPNQBSFEUP91BMPOF)PXFWFS JO

"MUIPVHIUIFHVJEFMJOFTGPS($JOEJDBUFUIBUBUMFBTU-/T

TVCHSPVQBOBMZTFT XFGPVOEUIBUBEKVWBOU9135NJHIUCFCFO



TIPVMECFSFNPWFE JUJTJNQPSUBOUUPFNQIBTJ[FUIBUUIFOVN

FGJDJBMJOQBUJFOUTXJUI-/QPTJUJWFEJTFBTF.PSFPWFS PVSEBUB

CFSPG-/TSFNPWFENJHIUWBSZBNPOHTVSHFPOTEFQFOEJOHPO

TVHHFTUFEUIBUUIF/SBUJPNJHIUCFBNPSFVTFGVMUPPMDPNQBSFE

QBUJFOUTFMFDUJPO UIFFYUFOUPG-/EJTTFDUJPO BOEUIFOVNCFSPG

UPUIF-/TUBUVTGPSTFMFDUJOHQBUJFOUTXIPDBOCFOFGJUGSPNBE

-/TFYBNJOFECZUIFQBUIPMPHJTUT*OGBDU UIF/SBUJPIBTBMTP

KVWBOU9135BGUFS%TVSHFSZ5IJTJTTVFJTCFJOHBEESFTTFEJO

CFFOQSPQPTFEBTBQSPHOPTUJDUPPMSFMBUFEUP-/NFUBTUBTFT

PVSPOHPJOHNVMUJJOTUJUVUJPOBM"35*45USJBM $MJOJDBM5SJBMT

5IFQSJODJQMFCFIJOEUIF/SBUJPBSPTFGSPNBEPVCUPWFSUIF

HPWJEFOUJGJFS /$5

XIJDIBJNTUPDPNQBSFUIFFGGFD

JNQBDUPGFYUFOEFE-/EJTTFDUJPOPOQSPHOPTJTBOEUIFEJTDVT

UJWFOFTTPGBEKVWBOU4NPOPUIFSBQZUPUIBUPG4PYBMJQMBUJO

TJPOBTUPXIFUIFSCFUUFSOPEBMTUBHJOHNJHIUCFDPNQMFUFMZ

409 BOE409QMVTSBEJPUIFSBQZ 40935 JOQBUJFOUTXJUI

SFTQPOTJCMFGPSUIJTFGGFDU5IFGBDUUIBUUIFDIBODFTPGGJOEJOHB

-/QPTJUJWF($BGUFS%TVSHFSZ

QPTJUJWF-/XBTIJHIFSGPSNPSFFYUFOTJWF-/EJTTFDUJPODPN QBSFEUPMJNJUFETVSHFSZ MFEUIFBVUIPSTUPQPTUVMBUFUIBUUIF

Conflicts of Interest

TJHOJGJDBODFPG-/TUBHFXPVMEWBSZBNPOHUIFQBUJFOUTEFQFOE JOHPOUIFOVNCFSPG-/TSFNPWFE 

/JUUJFUBM QSPQPTFEBUJFSDBUFHPSJ[BUJPOPGUIF/SBUJP  

/PQPUFOUJBMDPOGMJDUPGJOUFSFTUSFMFWBOUUPUIJTBSUJDMFXBT SFQPSUFE

_ _ BOE⾚ BOESFQPSUFEUIBUUIF/SBUJP XBTBOJOEFQFOEFOUQSFEJDUPSPGTVSWJWBMJOUIFJSTFSJFT5IF

References

GJOEJOHTPGUIFQSFTFOUTUVEZJOEJDBUFEUIBUUIF/SBUJPDPVMECF VTFEJOUIFTUSBUJGJDBUJPOPGUIFQBUJFOUTBGUFSDVSBUJWF%HBT

1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde

USFDUPNZ)PXFWFS UIF,BQMBO.FJFSDVSWFTGPS%'4BOE04

CJ. Surgical treatment of gastric cancer: 15-year follow-up re-

TVHHFTUFEUIBUUIFQSFWJPVTMZQSPQPTFEDBUFHPSJ[BUJPOPGUIF/

sults of the randomised nationwide Dutch D1D2 trial. Lancet

SBUJPTNJHIUCFUPPDPNQMJDBUFE XIJDIXBTTVQQPSUFECZUIF

Oncol 2010;11:439-449.

110 Kim Y, et al.

2. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H,

7. Marchet A, Mocellin S, Ambrosi A, de Manzoni G, Di Leo A,

Yamaguchi T, et al. Five-year outcomes of a randomized phase

Marrelli D, et al. The prognostic value of N-ratio in patients

III trial comparing adjuvant chemotherapy with S-1 versus

with gastric cancer: validation in a large, multicenter series.

surgery alone in stage II or III gastric cancer. J Clin Oncol

Eur J Surg Oncol 2008;34:159-165.

2011;29:4387-4393.

8. Costa Junior WL, Coimbra FJ, Batista TP, Ribeiro HS, Diniz

3. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW,

AL. Evaluation of N-ratio in selecting patients for adjuvant

et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer

chemoradiotherapy after D2-gastrectomy. Arq Gastroenterol

after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-

2013;50:257-263.

label, randomised phase 3 trial. Lancet Oncol 2014;15:13891396.

9. Nitti D, Marchet A, Olivieri M, Ambrosi A, Mencarelli R, Belluco C, et al. Ratio between metastatic and examined lymph

4. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, et al. Phase

nodes is an independent prognostic factor after D2 resection

III trial comparing capecitabine plus cisplatin versus capeci-

for gastric cancer: analysis of a large European monoinstitu-

tabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.

tional experience. Ann Surg Oncol 2003;10:1077-1085. 10. Coimbra FJ, Costa WL Jr, Montagnini AL, Diniz AL, Ribeiro HS, Silva MJ, et al. The interaction between N-category and N-

5. Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, et

ratio as a new tool to improve lymph node metastasis staging

al. Phase III trial to compare adjuvant chemotherapy with

in gastric cancer: results of a single cancer center in Brazil. Eur

capecitabine and cisplatin versus concurrent chemoradiother-

J Surg Oncol 2011;37:47-54.

apy in gastric cancer: final report of the adjuvant chemoradio-

11. Kunisaki C, Shimada H, Nomura M, Matsuda G, Otsuka Y,

therapy in stomach tumors trial, including survival and subset

Ono H, et al. Clinical impact of metastatic lymph node ratio in

analyses. J Clin Oncol 2015;33:3130-3136.

advanced gastric cancer. Anticancer Res 2005;25:1369-1375.

6. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger

12. Lee CM, Park SS, Kim JH. Current status and scope of lymph

C, et al. Gastric cancer, version 2.2013: featured updates to the

node micrometastasis in gastric cancer. J Gastric Cancer

NCCN Guidelines. J Natl Compr Canc Netw 2013;11:531-546.

2015;15:1-9.